FDA grants priority review for Roche’s Tecentriq combo sBLA
Roche has received the FDA priority review for its sBLA for adjuvant Tecentriq and Tecentriq Hybreza in combination with chemotherapy for colon cancer.
Read the full article on the original site.
Read Full Article